½ÃÀ庸°í¼
»óÇ°ÄÚµå
1444442
½Å°æ ³»½Ã°æ°Ë»ç : ½ÃÀå Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Neuroendoscopy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
½Å°æ ³»½Ã°æ°Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 32¾ï 7,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 42¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£(2024-2029³â) Áß 5.37%ÀÇ CAGR·Î ¼ºÀåÇÕ´Ï´Ù.
½Å°æ ³»½Ã°æ°Ë»ç ½ÃÀåÀº COVID-19 °¨¿°ÁõÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ Áß°£ Á¤µµÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ Àåºñ´Â ÁßÃ߽Űæ°è Áõ»óÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ´ë±â ¼ö¼úÀÌ ¿¬±âµÊ¿¡ µû¶ó ½Å°æ ³»½Ã°æÀÇ »ç¿ëÀÌ Æò¼Òº¸´Ù °¨¼ÒÇÏ°í ÅõÀÚµµ Æò¼Òº¸´Ù Àû½À´Ï´Ù. ¼±ÅÃÀû ½Ã¼úÀÌ Àç°³µÇ´õ¶óµµ ȯÀÚ´Â À§±â·Î ÀÎÇÑ ±äÀåÀ¸·Î ÀÎÇØ Áö¿¬µÈ °Ë»ç¿¡ Âü¿©ÇÏÁö ¾ÊÀ» °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ½Å°æ ³»½Ã°æ°Ë»ç ½ÃÀåÀº 2020³â ³»³» ¼ö¿ä°¡ °¨¼ÒÇßÁö¸¸, Áö¿¬µÈ ¼±ÅÃÀû ¼ö¼úÀÇ ¿Ï·á¿Í ¹é½Å ´öºÐ¿¡ ȯÀÚ°¡ ´õ ¾È½ÉÇÏ°í °Ë»ç¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¸é¼ 2021³â¿¡´Â ¸ÅÃâÀÌ Áõ°¡Çß½À´Ï´Ù.
½Å°æ ³»½Ã°æ°Ë»ç´Â ½Å°æ¿Ü°ú Àǻ簡 Á¾¾çÀ» Ž»öÇÏ°í Á¾¾ç¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï ³»½Ã°æÀ» Âø¿ëÇÏ¿© ½ÃÇàÇÕ´Ï´Ù. ½Å°æ¿Ü°ú ÀÇ»ç´Â Á¾¾çÀ» Á¦°ÅÇϰųª Á¾¾ç »ùÇÃÀ» äÃë(»ý°Ë)Çϱâ À§ÇØ ³»½Ã°æ¿¡ Ư¼ö ±â±¸¸¦ ºÎÂøÇÕ´Ï´Ù. Á¾Á¾ Áý°Ô³ª °¡À§°¡ ´Þ¸° Ãß°¡ ³»½Ã°æÀ» »ç¿ëÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ´Â Ä¡À¯¿¡ ½Ã°£ÀÌ ¿À·¡ °É¸®´Â ÀüÅëÀûÀÎ °³µÎ¼ú°ú´Â ´ëÁ¶ÀûÀÔ´Ï´Ù. ¼ö¼ú ÈÄ ÅëÁõÀÌ ÁÙ¾îµì´Ï´Ù. ¶ÇÇÑ ½Å°æ ³»½Ã°æ ½Ã¼úÀº ȯÀÚ¿¡°Ô ÃÖ¼ÒÇÑÀÇ ÈäÅ͸¦ ³²±é´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡Àº ÀÇÇа迡¼ ³Î¸® °í·ÁµÇ°í ÀÖÀ¸¸ç, µû¶ó¼ ÀÌ·¯ÇÑ ½Ã¼úÀº Àü ¼¼°è¿¡¼ Á¡Á¡ ´õ º¸Æíȵǰí ÀÖ½À´Ï´Ù. µû¶ó¼ ±âÁ¸ ³ú ¼ö¼ú¿¡ ºñÇØ ½Å°æ ³»½Ã°æ ¼ö¼úÀÇ ÀåÁ¡Àº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Á¤ºÎÀÇ À¯¸®ÇÑ Á¤Ã¥ µîÀÌ ÀÖ½À´Ï´Ù.
À¯¿¬ÇÑ ½Å°æ³»½Ã°æÀº ºûÀ» Àü´ÞÇÏ°í À¯¿¬ÇÑ Åõ¸í ¼¶À¯¸¦ ÅëÇØ °üÂûÀÚ¿¡°Ô À̹ÌÁö¸¦ Àü´ÞÇÏ¿© ½Åü ³»ºÎ¸¦ °Ë»çÇÏ°í Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ±¤ÇÐ ±â±âÀÔ´Ï´Ù. À¯¿¬ÇÑ ½Å°æ ³»½Ã°æ°ú °ü·ÃµÈ ¸î °¡Áö ÀåÁ¡À¸·Î ÀÎÇØ À¯¿¬ÇÑ ½Å°æ ³»½Ã°æ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯¿¬ÇÑ ½Å°æ ³»½Ã°æÀÇ ÁÖ¿ä ÀåÁ¡ Áß Çϳª´Â ¸ð¾çÀÌ °íÁ¤µÇ¾î ÀÖÁö ¾Ê°í °î¼± ±Ëµµ¸¦ µû¶ó Æ÷Àå ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ¿¬¼º ³»½Ã°æÀº ÀÏ¹Ý ½Ã¾ß·Î´Â º¼ ¼ö ¾ø´Â Àå±âÀÇ ³»ºÎ¸¦ ½Ã°¢ÈÇÒ ¼ö ÀÖ½À´Ï´Ù. 2019³â 6¿ù¿¡ ¹ßÇ¥µÈ '¸¸¼º °æ¸·ÇÏ Ç÷Á¾ Ä¡·á¿¡¼ µå¶óÀÌ ÇÊµå ±â¼ú°ú °áÇÕµÈ ¿¬¼º ½Å°æ ³»½Ã°æÀÇ È¿°ú ºÐ¼®'À̶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡ µû¸£¸é ¿¬¼º ³»½Ã°æ Àåºñ´Â ¸¸¼º °æ¸·ÇÏ Ç÷Á¾(CSDH)¿¡ »ç¿ëµÇ¾ú½À´Ï´Ù. ÀÌ ¿¬±¸´Â ¿¬¼º ½Å°æ³»½Ã°æ°ú µå¶óÀÌ ÇÊµå ±â¼ú(DFT)À» °áÇÕÇÏ¿© CSDH ȯÀÚ¸¦ Ä¡·áÇÏ´Â °ÍÀÌ È¿°úÀûÀ̶ó´Â °ÍÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù.
¶ÇÇÑ 2020³â 5¿ù¿¡ ¹ßÇ¥µÈ '³úÈ³ó¼º Ä÷º¼ÇÀÇ ³»½Ã°æ Ä¡·áÀÇ »õ·Î¿î °üÁ¡: Ç¥Àû, ±â¼ú, »ç·Ê ½Ã¸®Áî °á°ú ¹× ¹®Çå °³¿ä'´Â È³ó¼º µÎ°³³» °¨¿° Ä¡·á¿¡ ÀÖÀ¸¸ç, À¯¿¬ÇÑ ³»½Ã°æÀÌ È¿°úÀûÀ̶ó´Â °ÍÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±¸´Â ½ÃÀå ¼ºÀå¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ±â¼úÀûÀ¸·Î Áøº¸µÈ Á¦Ç°µéÀÌ ½ÃÀå¿¡ Ãâ½ÃµÇ¸é¼ ½ÃÀå ¼ºÀåÀÌ ´õ¿í °¡¼Ó鵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î Ä® ½ºÅçÃ÷(Carl Stoltz)°¡ °³¹ßÇÑ 'Ç÷º¼ºí ºñµð¿À ½Å°æ³»½Ã°æ'Àº ³ú¼öµÎÁõ Ä¡·á¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¹Ì±¹ ½ÄÇ°ÀǾ౹(FDA)ÀÇ ½ÂÀÎÀ» ¹ÞÀº À¯ÀÏÇÑ ºñµð¿À ½Å°æ³»½Ã°æÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°Àº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ÀÌ ºÐ¾ß ½ÃÀåÀº ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖÀ¸¸ç, ¾ÕÀ¸·Îµµ ÀÌ·¯ÇÑ Ãß¼¼´Â Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Å°æ ³»½Ã°æ°Ë»ç ½ÃÀåÀº ÁÖ·Î Á¤ºÎÀÇ ±¸»ó °È¿Í ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
¹Ì±¹ ±¹¸³È¯°æº¸°Ç°úÇבּ¸¼Ò¿¡ µû¸£¸é ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½Å°æÅðÇ༺ Áúȯ¿¡ °É¸± À§ÇèÀÌ ±Þ°ÝÈ÷ Áõ°¡ÇÏ°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀÌ´Â ´ëºÎºÐÀÇ ¹Ì±¹ÀÎÀÌ ÇâÈÄ ¼ö½Ê³â°£ ½Å°æ ÅðÇ༺ Áúȯ¿¡ °É¸± °¡´É¼ºÀÌ ÀÖÀ½À» ½Ã»çÇÕ´Ï´Ù. ¹Ì±¹ Àα¸ Á¶»ç±¹ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2019³â¿¡´Â ¾à 5,400¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ 65¼¼ ÀÌ»óÀÔ´Ï´Ù. ¶ÇÇÑ ¾ËÃ÷ÇÏÀ̸Ӻ´ Çùȸ¿¡ µû¸£¸é 2020³â ÇöÀç 580¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ ¾ËÃ÷ÇÏÀ̸Ӻ´À» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù.
¶ÇÇÑ ¹Ì±¹ Áß¾Ó³úÁ¾¾çµî·Ï±â°üÀÇ 2020³â ºÐ¼®¿¡ µû¸£¸é 2013-2017³â±îÁö ³úÁ¾¾ç(¾Ç¼º ¹× ºñ¾Ç¼º)ÀÇ ¹ß»ý·üÀº 100,000¸í´ç ¾à 23.79¸íÀ¸·Î ±â·ÏµÇ¾ú½À´Ï´Ù. ¹ß»ýÇÑ Á¾¾ç ¼ö´Â ¾à 415,411°ÇÀÔ´Ï´Ù. ¶ÇÇÑ ¼ö¼ú ÈÄ ÅëÁõÀÌ ÀûÀº ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼ Á¶»ç ´ë»ó ½ÃÀå¿¡¼ ½Å°æ ³»½Ã°æ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦Ç° ½ÂÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ Áö¿ª ½ÃÀåµµ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 1¿ù ¹Ì±¹ ½ÄÇ°ÀǾ౹(FDA)Àº ClearMind BiomedicalÀÌ ¼³°èÇÑ Axonpen ½Ã½ºÅÛÀ» ½ÂÀÎÇß½À´Ï´Ù. ÀÌ°ÍÀº µÎ°³³» Á¶Á÷ ¹× ü¾×ÀÇ ½Ã°¢È¿Í ¼ö¼ú Áß Á¶Á÷ ¹×/ ¶Ç´Â ü¾×ÀÇ Á¦¾îµÈ ÈíÀÔ¿¡ »ç¿ëµÇ´Â »õ·Î¿î ½Å°æ ³»½Ã°æÀÔ´Ï´Ù. µû¶ó¼ ½Å°æ ÁúȯÀÇ ºÎ´ã Áõ°¡¿Í ´õºÒ¾î ÃÖ¼Ò Ä§½À ¼ö¼ú ¹× ½ÅÁ¦Ç°¿¡ ´ëÇÑ ±â¼ú ¹ßÀü¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½Å°æ³»½Ã°æ ½ÃÀåÀÇ ¼¼°è ±â¾÷Àº Adeor Medical AG, B. Braun Melsungen AG, Clarus Medical, KARL STORZ SE & Co. Technologie GmbH, Tonglu Wanhe Medical Instrument µîÀÔ´Ï´Ù.
The Neuroendoscopy Market size is estimated at USD 3.27 billion in 2024, and is expected to reach USD 4.25 billion by 2029, growing at a CAGR of 5.37% during the forecast period (2024-2029).
The neuroendoscopes market has been moderately impacted by the COVID-19 pandemic. These devices are used for the treatment of conditions of the central nervous system. As elective surgeries have been postponed, neuroendoscopes have been less utilized than usual and thus suffer from less investment than usual as well. Even as elective procedures resume, it is likely that patients will not attend their delayed screening due to nervousness from the crisis. The neuroendoscopes market suffered from less demand throughout 2020, though revenue rose in 2021 as delayed elective procedures were completed, and vaccines helped patients feel safer about completing screenings.
Neuroendoscopy is performed using an endoscope on end to allow the neurosurgeon to navigate and access the tumor. In order to remove a tumor or take a sample of it (a biopsy), neurosurgeons attach special instruments to the endoscope, often an additional endoscope with forceps and scissors on end, as opposed to conventional open brain surgery, which requires more time for healing post-surgery and induces less pain. Also, neuroendoscopic procedures cause minimal scarring in patients. These benefits are being considered widely in the medical community, and therefore, these procedures are becoming more common worldwide. Hence, the benefits of neuroendoscopic surgery over conventional brain surgery are expected to drive the growth of the market. Other factors that will affect the growth of this market include the rising prevalence of neurological disorders and favorable government initiatives.
Flexible neuroendosocpes are optic instrument that transmits light and carries images back to the observer through flexible transparent fibers and is used to inspect and treat interior portions of the body. Several advantages associated with flexible neuroendoscopy are expected to drive the demand for flexible neuroendoscopes. One of the primary advantages of flexible neuroendoscopes is that their geometry is not fixed and can be paved along a curved trajectory. Flexible endoscopes provide visibility of the internal side of the organ, which generally cannot be seen with a normal view. According to the study titled, '' Efficacy analysis of flexible neuroendoscopy combined with dry-field techniques in the treatment of chronic subdural hematoma'', published in June 2019, a flexible endoscopy device was used for chronic subdural hematoma (CSDH). The study revealed that flexible neuroendoscopy was efficient in combination with dry-field techniques (DFTs) in the treatment of CSDH patients.
Furthermore, as per a study titled. 'New perspectives in the endoscopic treatment of brain purulent collections: targets, techniques, results in a case series, and overview of the literature', published in May 2020, showed that flexible endoscopy in the treatment of purulent intracranial infections was effective. Such studies are expected to support market growth. The presence of technologically advanced products in the market is further expected to accelerate the market growth. For instance, ''flexible video neuro endoscope'' developed by Karl Storz GmbH is used in the treatment of hydrocephalus. It is the only Food & Drug Administration-approved video neuroendoscopes. Such products are expected to impact market growth positively.
Therefore, with the above-mentioned factors, the market is expected to boost in this segment.
North America currently dominates the market and is expected to continue the same trend. The neuroendoscopy market is mainly driven by factors such as rising government initiatives and the increasing prevalence of neurological disorders.
In the United States, the risk of being affected by a neurodegenerative disease is increasing dramatically, with the rising geriatric population, as per the National Institute of Environmental Health Sciences. This indicates that most Americans may be affected by neurodegenerative diseases in the coming decades. As per the data of the United States Census Bureau, in 2019, about 54 million Americans are aged 65 years and above. Furthermore, according to the Alzheimer's Association, more than 5.8 million Americans suffer from Alzheimer's disease as of 2020.
Furthermore, as per the analysis of 2020 by the Central Brain Tumor Registry of the United States, in 2013-2017, the incidence rate of brain tumors (malignant and non-malignant) was recorded to be about 23.79 cases per 100,000, with the total count of nearly 415,411 incident tumors. In addition, the rising preference of people toward minimally invasive surgery as it cause less post-operative pain is also expected to boost the demand for neuroendoscopes in the market studied. The increasing product approvals are also expected to thrive in the market in this region. For instance, in January 2021, the United States Food and Drug Administration approved Axonpen System designed by ClearMind Biomedical. It is a novel neuroendoscopes that is used in the visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery. Thus, with the rising burden of neurological disorders along with the rising preference for minimally invasive surgeries and technological advancements with respect to new products, it is expected to contribute to market growth.
The global players in the neuroendoscopy market are Adeor Medical AG, B. Braun Melsungen AG, Clarus Medical, KARL STORZ SE & Co. KG, Machida Endoscope Co. Ltd, Schindler Endoskopie Technologie GmbH, and Tonglu Wanhe Medical Instrument Co. Ltd.